Literature DB >> 34787829

Cytological Diagnostic Procedures in Malignant Mesothelioma.

Christian Biancosino1, Lea Isabell Shari van der Linde2, Guido Sauter2, Florian Stellmacher3, Marcus Krüger4, Lutz Welker2.   

Abstract

Malignant mesotheliomas (MM) are rare tumors with high mortality rates, whose incidence varies regionally and nationally, and the diagnosis is difficult. Histology-based diagnosis is considered the gold standard despite its low sensitivity of 57-84%. However, recent advances in cytological analysis offer promise for diagnostic advancements. In this study, we reappraised the current cytological guidelines for the MM diagnosis and concluded on their practicability and reliability. The study included 5731 consecutive specimens of pleural effusions from 4552 patients (3026 males of the average age of 67.5 years and 1526 females of the average age of 65.4 years) between December 2017 and January 2000. Out of these patients, 444 (9.8%) were diagnosed with MM. The effusions were examined by immunocytochemistry using routine Giemsa staining. Additionally, hyaluronic acid (HA) was assessed. Cytological findings confirmed 223 out of the 444 MM. The additional 88 cases with negative cytology were corroborated by supplemental assessments of HA above 30 mg/L. Cytological evaluation accomplished the sensitivity of 0.50, specificity of 0.99, and a positive predictive value (PPV) of 0.97 for MM diagnosis. The use of HA determination raised the sensitivity to 0.70 without affecting the specificity or PPV. We conclude that cytological evaluation of effusions aided by the assessment of HA demonstrates the diagnostic sensitivity and specificity for MM no less than the hitherto standard histological evaluation. The cytology-based MM diagnosis may thus be routinely considered when MM is suspected and may offer confirmatory advantages in difficult or doubtful diagnostic cases.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cytology; Diagnosis; Malignancy; Mesothelioma; Pleural effusion

Mesh:

Year:  2022        PMID: 34787829     DOI: 10.1007/5584_2021_680

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  45 in total

Review 1.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

Review 2.  The separation of benign and malignant mesothelial proliferations.

Authors:  Andrew Churg; Francoise Galateau-Salle
Journal:  Arch Pathol Lab Med       Date:  2012-10       Impact factor: 5.534

3.  The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.

Authors:  Biswajit Chakrabarti; Ida Ryland; John Sheard; Christopher J Warburton; John E Earis
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

4.  Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.

Authors:  R F Adams; W Gray; R J Davies; F V Gleeson
Journal:  Chest       Date:  2001-12       Impact factor: 9.410

5.  Latency periods in asbestos-related mesothelioma of the pleura.

Authors:  C Bianchi; L Giarelli; G Grandi; A Brollo; L Ramani; C Zuch
Journal:  Eur J Cancer Prev       Date:  1997-04       Impact factor: 2.497

6.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

7.  Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy.

Authors:  Prachi P Agarwal; Jean M Seely; Fred R Matzinger; Robert M MacRae; Rebecca A Peterson; Donna E Maziak; Carole J Dennie
Journal:  Radiology       Date:  2006-09-27       Impact factor: 11.105

Review 8.  Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.

Authors:  Raphael Bueno; Jason Reblando; Jonathan Glickman; Michael T Jaklitsch; Jeanne M Lukanich; David J Sugarbaker
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

9.  The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  2008-07-18       Impact factor: 5.087

10.  Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.

Authors:  Lucian R Chirieac; Justine A Barletta; Beow Y Yeap; William G Richards; Tamara Tilleman; Raphael Bueno; Elizabeth H Baldini; John Godleski; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.